Which CLL patients would benefit from intensive therapy?
Overcoming the challenges of evolving standards of care in CLL: advice for community physicians
Ibrutinib vs chlorambucil in CLL patients not suitable for chemotherapy
Follow-up results of looking at treatment with ibrutinib on CLL patient survival and adverse events
Targeted therapies for CLL: new data and unanswered questions